Company news

Sun Pharmaceutical Industries Limited news in 2026

Sun Pharmaceutical Industries Limited's news releases, calls and decks from 2026, newest first.

View company

Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated October 30, 2026, titled "ILUMYA® (tildrakizumab-asmn) approved in the U.S. for the Treatment of Adults with Active Psoriatic Arthritis".

October 29, 2026

Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated October 23, 2026.

October 23, 2026

Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated October 20, 2026.

October 20, 2026

Sun Pharma Establishes Endowed Professorship at Mount Sinai to Advance Dermatologic Care

October 6, 2026

New LEQSELVI® (deuruxolitinib) Two-Year Data in Severe Alopecia Areata Showed Sustained Efficacy and Safety at EADV Congress 2026

October 1, 2026

Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated October 01, 2026, titled "New LEQSELVI® (deuruxolitinib) Two-YearData in Severe Alopecia Areata Showed Sustained Efficacy and Safety at EADV Congress 2026".

October 1, 2026

LIB Therapeutics and Sun Pharma Announce Global Licensing, Commercialization and Manufacturing Agreement for Lerodalcibep, a Novel PCSK9 Inhibitor, Ex-US and China; Lerodalcibep (Lyrokaul®) Approved in the EU

September 28, 2026

Sun Pharmaceutical Industries Limited Press Release Sep 28 2026

September 27, 2026

Sun Pharma Launches (C)Taro-Methylphenidate ER, the First and Only Bioequivalent to Concerta® with an Osmotic Delivery System

September 24, 2026

First-Ever Standardized U.S. Treatment Recommendations Issued for Adults with Severe Alopecia Areata; Sun Pharma Welcomes Milestone

September 22, 2026

Sun Pharma and Christian Siriano Launch "Regrowth Restyled" to Inspire Adults Living with Severe Alopecia Areata

September 17, 2026

Sun Pharmaceutical Industries Limited Press Release Sep 01 2026

August 31, 2026

Sun Pharmaceutical Industries Limited Press Release Jul 29 2026

July 29, 2026

Sun Pharmaceutical Industries Limited Press Release Jul 24 2026

July 23, 2026

Sun Pharmaceutical Industries Limited Press Release Jul 15 2026

July 14, 2026

American Skin Association annual gala recognizes Sun Pharma with corporate leadership award

June 3, 2026

At the ASCO® 2026 Annual Meeting, Sun Pharma to Present Pivotal Long-Term Follow-up Data on UNLOXCYT™ (cosibelimab-ipdl)

May 26, 2026

Press Release May 26 2026

May 26, 2026

Sun Pharmaceutical Industries, Inc. (Sun Pharma) Initiates Voluntary U.S. Nationwide Recall of DOXOrubicin Hydrochloride Liposome...

May 13, 2026

Sun Pharma To Acquire Organon

May 8, 2026

Press Release Apr 27 2026

April 27, 2026

Sun Pharma signs Definitive Agreement to Acquire Organon

April 26, 2026

Press Release Mar 27 2026

March 27, 2026

Press Release Mar 21 2026

March 21, 2026

Press Release Mar 16 2026

March 16, 2026

Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUMYA® (tildrakizumab-asmn) for the Treatment of Adults with Active Psoriatic Arthritis

March 16, 2026

Sun Pharma Showcases Data Across its Dermatology & Immunology Portfolio at 2026 Winter Clinical Miami

February 27, 2026

Sun Pharma Introduces SUNday, Highlighting the Everyday Realities of Skin Cancer Care

February 5, 2026

Press Release Jan 23 2026

January 23, 2026

Sun Pharmaceutical Industries Limited Press Release Jan 23 2026

January 22, 2026

Sun Pharma Announces the Availability of UNLOXCYT for Advanced Cutaneous Squamous Cell Carcinoma

January 16, 2026

Press Release Jan 15 2026

January 15, 2026

Sun Pharma Announces the Availability of UNLOXCYT™ (cosibelimab-ipdl) for Advanced Cutaneous Squamous Cell Carcinoma (aCSCC)

January 15, 2026

ILUMYA® (tildrakizumab) Pen (Auto-Injector) Now Available for Canadians Living with Moderate-to-Severe Plaque Psoriasis

January 7, 2026

Sun Pharma Launches ILUMYA® In India

January 2, 2026

Calls in 2026

Decks in 2026